- Home
- GPN vs RVPHW Comparison
GPN vs RVPHW Comparison
Compare GPN & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPN
- RVPHW
- Stock Information
- Founded
- GPN 1967
- RVPHW 2018
- Country
- GPN United States
- RVPHW United States
- Employees
- GPN N/A
- RVPHW 14
- Industry
- GPN Business Services
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- GPN Consumer Discretionary
- RVPHW Health Care
- Exchange
- GPN Nasdaq
- RVPHW Nasdaq
- Market Cap
- GPN N/A
- RVPHW N/A
- IPO Year
- GPN 2001
- RVPHW N/A
- Fundamental
- Price
- GPN $85.76
- RVPHW $0.03
- Analyst Decision
- GPN Buy
- RVPHW
- Analyst Count
- GPN 28
- RVPHW 0
- Target Price
- GPN $115.74
- RVPHW N/A
- AVG Volume (30 Days)
- GPN 2.2M
- RVPHW 22.4K
- Earning Date
- GPN 08-06-2025
- RVPHW 03-14-2025
- Dividend Yield
- GPN 1.17%
- RVPHW N/A
- EPS Growth
- GPN 22.93
- RVPHW N/A
- EPS
- GPN 6.19
- RVPHW N/A
- Revenue
- GPN $10,097,805,000.00
- RVPHW N/A
- Revenue This Year
- GPN N/A
- RVPHW N/A
- Revenue Next Year
- GPN $6.34
- RVPHW N/A
- P/E Ratio
- GPN $13.86
- RVPHW N/A
- Revenue Growth
- GPN 3.23
- RVPHW N/A
- 52 Week Low
- GPN $65.93
- RVPHW $0.13
- 52 Week High
- GPN $120.00
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- GPN 63.18
- RVPHW N/A
- Support Level
- GPN $82.96
- RVPHW N/A
- Resistance Level
- GPN $84.67
- RVPHW N/A
- Average True Range (ATR)
- GPN 2.03
- RVPHW 0.00
- MACD
- GPN 0.41
- RVPHW 0.00
- Stochastic Oscillator
- GPN 94.77
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.